ATTR amyloidosis in patients with heart failure with preserved ejection fraction and a cardiac implantable electronic device

Completed

• Conditions: Protein misfolding disease; 10082206

• Registration Number: NL-OMON49286
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Heart failure, NYHA 2 or 3.
CIED
LVEF > 40%
NT-proBNP >400 ng/L sinus rhythm; > 1200 ng/L atrial fibrillation

Exclusion Criteria

Unwilling or unable to sign informed consent.
Life expectancy < 1 year.
Signficant coronary artery disease or myocardial infarction < 3 months

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The prevalence of ATTR, measured by bone scintigraphy, in HFpEF patients with<br /><br>CIED. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>A) To assess the frequency of (re-)hospitalization of HFpEF patients with a<br /><br>CIED diagnosed with or without transthyretin amyloid cardiomyopathy.<br /><br><br /><br>B) To assess the clinical characteristics of HFpEF patients also diagnosed with<br /><br>transthyretin amyloid cardiomyopathy.<br /><br><br /><br>C) To assess the clinical characteristics of HFpEF patients that decrease the<br /><br>likelihood of the presence of transthyretin amyloid cardiomyopathy.<br /><br><br /><br>D) To assess the mortality of HFpEF patients with a CIED diagnosed with or<br /><br>without transthyretin amyloid cardiomyopathy.</p><br>